Lv7
4210 积分 2023-10-10 加入
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
1个月前
已完结
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
1个月前
已完结
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
1个月前
已完结
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
1个月前
已完结
RAMP1 and RAMP3 Differentially Control Amylin’s Effects on Food Intake, Glucose and Energy Balance in Male and Female Mice
1个月前
已完结
Effects of Pramlintide in Patients with Type 2 Diabetes Mellitus: An Analysis Using Daily Insulin Dose Tertiles
1个月前
已关闭
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
1个月前
已完结
The story of amylin: from physiology to therapy
1个月前
已完结
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
1个月前
已完结
The evolving landscape of obesity pharmacotherapy
1个月前
已完结
皖公网安备34019202002308
